PomegraPharma Stocks Jump 4% After Trial Results, Deals
Why are pharma stocks up today?
Eli Lilly (LLY), Merck (MRK), AstraZeneca (AZN) and Bristol-Myers (BMY) stocks each rose about 4% on Wednesday, with Lilly near $1,211, as trial results, deals and analyst upgrades lifted healthcare.
Key numbers
| Eli Lilly (LLY) share price | $1,211.14+3.8% from $1,166.51 |
|---|---|
| Merck (MRK) share price | $147.14+3.6% from $141.98 |
| AstraZeneca (AZN, NYSE) share price | $161.21+3.5% from $155.82 |
| Bristol-Myers (BMY) share price | $58.91+4% from $56.67 |
| S&P 500 | 7,718.94-1.11% |
| US inflation, September (yearly) | 3.7%vs 3.6% expected |
What happened
Eli Lilly (LLY), Merck (MRK), AstraZeneca (AZN) and Bristol-Myers (BMY) stocks each rose about 4% on Wednesday, with Lilly near $1,211, as trial results, deals and analyst upgrades lifted healthcare. The gains came as September prices rose 3.7% from a year earlier, hotter than expected, and the S&P 500 fell 1.1%. Merck said it will present results from three late-stage cancer trials this month. AstraZeneca has put $2 billion into cancer-drug maker Summit Therapeutics. Analysts raised Lilly price targets.
Why it matters
Eli Lilly, Merck, AstraZeneca and Bristol-Myers rose while the S&P 500 fell 1.1%, a sign investors leaned toward drugmakers when tech stocks sank. Their gains rest on new medicines. Merck, for example, needs successors as cheaper copies of its top cancer drug Keytruda arrive in 2028–2029. Lilly reports earnings on October 29, so the next test is close.
Who this affects
- MarketmixedMedium impact
- Healthcare gained while tech fell, shifting money between sectors.
- CompanybullishMedium impact
- Lilly shareholders gained as analysts raised targets before earnings.
- CompetitorsbullishMedium impact
- Merck, AstraZeneca and Bristol-Myers rose alongside Lilly.
- IndustrybullishMedium impact
- Drugmakers drew investors as inflation worries hit tech stocks.
Eli Lilly vs Merck, AstraZeneca, Bristol-Myers Squibb
How we got here
AstraZeneca agrees $2B equity investment in Summit Therapeutics and a cancer-drug trial collaboration
Bristol-Myers reports positive late-stage results for RYZ101 and admilparant
Merck announces three pivotal cancer trial results for the ESMO 2026 conference
September inflation hits 3.7%; S&P 500 falls 1.1% while drugmakers rise
What to watch
- Merck presents three late-stage cancer trial results at the ESMO conference; investor event October 262026-10-23
- Eli Lilly reports third-quarter earnings; analysts expect strong Mounjaro and Zepbound sales2026-10-29
Educational content only. Not investment advice.
More briefsAll briefs →
CoreWeave Stock Falls 16% as Bond Yields Near 15%
CoreWeave (CRWV) closed at $65.78 as Oracle slid 9%, with investors wary of AI companies' growing debt.
Gold Drops to $4,100 as Rate-Hike Odds Climb
Gold (XAU/USD) logs a third straight loss and silver slides over 5% after hot US inflation data
Brent Crude Rises 0.8% to $106.56 as Energy Truce Falters
Brent crude (BZ=F) edged up as Ukraine said Russia hit six energy sites and Italy faulted US diesel relief.